

**ASX Code: PRR**

**Company Announcement**

1<sup>st</sup> December 2009

**COMPLETION OF SHARE PURCHASE PLAN**

Prima Biomed Limited (ASX:PRR) advises that it yesterday completed the issue of 80,401,244 shares at an issue price of 14 cents each under the terms of the Share Purchase Plan announced on 16 October 2009 for gross proceeds of \$11,256,108.

An Appendix 3B is attached.

ENDS

**For further information please contact:**

Mr Martin Rogers  
Executive Director  
Prima BioMed Limited  
Ph: 0428 268 357  
E: [martin.rogers@primabiomed.com.au](mailto:martin.rogers@primabiomed.com.au)

James Moses  
Investor and Media Relations  
Mandate Corporate  
Ph: 0420 991 574  
E: [james@mandatecorporate.com.au](mailto:james@mandatecorporate.com.au)

Website: [www.primabiomed.com.au](http://www.primabiomed.com.au)

For personal use only

## Appendix 3B

### New Issue Announcement, Application for Quotation of Additional Securities and Agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

**Name of Entity:**

Prima Biomed Limited (ASX: PRR)

**ABN:**

90 009 237 889

We (the entity) give ASX the following information.

#### Part 1 - All Issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

- |   |  |  |
|---|--|--|
| 1 | +Class of +securities issued or to be issued   | a) Ordinary Fully Paid Shares (PRR)<br>b) Ordinary Fully Paid Shares (PRR)                 |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued  | a) 80,401,244<br>b) 333,500  |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | a) Pari passu with existing ordinary shares<br>b) Pari passu with existing ordinary shares |

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3B**  
**New issue announcement**

<p>4 Do the <sup>+</sup>securities rank equally in all respects from the date of allotment with an existing <sup>+</sup>class of quoted <sup>+</sup>securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	<p>a) Yes, (PRR)  b) Yes, (PRR)</p>						
<p>5 Issue price or consideration</p>	<p>a) \$0.14 per ordinary share  b) \$0.02 per ordinary share</p>						
<p>6 Purpose of the issue  (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>a) Share Purchase Plan  b) Exercise of PRRO Options</p>						
<p>7 Dates of entering <sup>+</sup>securities into uncertificated holdings or despatch of certificates</p>	<p>a) 30 November 2009  b) 27 November 2009 to 30 November 2009</p>						
<p>8 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (including the securities in clause 2 if applicable)</p>	<table border="1"> <thead> <tr> <th data-bbox="694 1355 869 1422">Number</th> <th data-bbox="869 1355 1260 1422"><sup>+</sup>Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="694 1422 869 1512">629,498,979</td> <td data-bbox="869 1422 1260 1512">Ordinary fully paid shares (PRR)</td> </tr> <tr> <td data-bbox="694 1512 869 1677">126,791,898</td> <td data-bbox="869 1512 1260 1677">Options exercisable at \$0.02 on or before 31 December 2011 (PRRO)</td> </tr> </tbody> </table>	Number	<sup>+</sup> Class	629,498,979	Ordinary fully paid shares (PRR)	126,791,898	Options exercisable at \$0.02 on or before 31 December 2011 (PRRO)
Number	<sup>+</sup> Class						
629,498,979	Ordinary fully paid shares (PRR)						
126,791,898	Options exercisable at \$0.02 on or before 31 December 2011 (PRRO)						

+ See chapter 19 for defined terms.

For personal use only

9 Number and <sup>+</sup>class of all <sup>+</sup>securities not quoted on ASX (including the securities in clause 2 if applicable)

Number	+Class			
	Amount	Exercise Price	Expiration Date	ASX Code
300,000	\$0.2000		06 August 2010	PRRAK
15,000,000	\$0.0629		20 July 2014	PRRAI
1,547,988	\$0.1053		10 August 2014	PRRAM
1,766,784	\$0.1325		9 September 2014	PRRAQ
1,884,253	\$0.2231		10 October 2014	PRRAO
1,884,253	\$0.2685		9 November 2014	PRRAS
<b>22,383,278</b>	<b>Total</b>			

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Unchanged

## Part 2 - Bonus Issue or Pro Rata Issue

11 Is security holder approval required?

12 Is the issue renounceable or non-renounceable?

13 Ratio in which the <sup>+</sup>securities will be offered

14 <sup>+</sup>Class of <sup>+</sup>securities to which the offer relates

15 <sup>+</sup>Record date to determine entitlements

16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

17 Policy for deciding entitlements in relation to fractions

<sup>+</sup> See chapter 19 for defined terms.

For personal use only

**Appendix 3B**  
**New issue announcement**

---

- 18 Names of countries in which the entity has <sup>+</sup>security holders who will not be sent new issue documents  
Note: Security holders must be told how their entitlements are to be dealt with.  
Cross reference: rule 7.7.
- 19 Closing date for receipt of acceptances or renunciations
- 20 Names of any underwriters
- 21 Amount of any underwriting fee or commission
- 22 Names of any brokers to the issue
- 23 Fee or commission payable to the broker to the issue
- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of <sup>+</sup>security holders
- 25 If the issue is contingent on <sup>+</sup>security holders' approval, the date of the meeting
- 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if applicable)
- 29 Date rights trading will end (if applicable)

---

<sup>+</sup> See chapter 19 for defined terms.

For personal use only

- 30 How do +security holders sell their entitlements *in full* through a broker?
- 31 How do +security holders sell *part* of their entitlements through a broker and accept for the balance?
- 32 How do +security holders dispose of their entitlements (except by sale through a broker)?
- 33 +Despatch date

### Part 3 - Quotation of Securities

*You need only complete this section if you are applying for quotation of securities*

- 34 Type of securities  
(tick one)
- (a)  Securities described in Part 1
- (b)  All other securities  
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

##### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

- 35  If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
- 36  If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over
- 37  A copy of any trust deed for the additional +securities

#### Entities that have ticked box 34(b)

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3B**  
**New issue announcement**

38 Number of securities for which  
 +quotation is sought

--

39 Class of +securities for which  
 quotation is sought

--

40 Do the +securities rank equally in all  
 respects from the date of allotment  
 with an existing +class of quoted  
 +securities?

If the additional securities do not  
 rank equally, please state:

- the date from which they do
- the extent to which they  
 participate for the next dividend,  
 (in the case of a trust,  
 distribution) or interest payment
- the extent to which they do not  
 rank equally, other than in  
 relation to the next dividend,  
 distribution or interest payment

--

41 Reason for request for quotation now  
 Example: In the case of restricted securities, end of  
 restriction period

(if issued upon conversion of another  
 security, clearly identify that other  
 security)

--

42 Number and +class of all +securities  
 quoted on ASX (*including* the  
 securities in clause 38)

<b>Number</b>	<b>+Class</b>

+ See chapter 19 for defined terms.

For personal use only

---

**Quotation Agreement**

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign Here:



Company Secretary

Date: Tuesday 1<sup>st</sup> December 2009

Print Name:

Phillip Hains



The CFO Solution

---

1/12/2009

---

+ See chapter 19 for defined terms.

For personal use only